Physician profile
Shirly H Ramchandani
NPI 1609802180
$2,262.28
in general payments reported to CMS, 2019-2025
17 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Obesity Medicine (Internal Medicine) provider received nationally (typical 2025 total: $202).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $104 · 2021: $267 · 2022: $431 · 2023: $462 · 2024: $257 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,106.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $986.41 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Rhythm Pharmaceuticals, INC. | $199.91 | 2023-2024 | Imcivree, Imcivree |
| Celgene Corporation | $192.63 | 2021-2023 | Zeposia |
| Janssen Biotech, INC. | $180.19 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $166.97 | 2022-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $99.79 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.87 | 2022-2023 | Trulance |
| Redhill Biopharma INC. | $62.23 | 2021-2022 | |
| Braintree Laboratories, INC. | $54.36 | 2022-2025 | Suflave |
| Abbvie INC. | $50.97 | 2022-2023 | |
| Pfizer INC. | $45.57 | 2022-2024 | |
| Genzyme Corporation | $36.80 | 2024 | |
| Madrigal Pharmaceuticals | $35.46 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $31.96 | 2025 | Dupixent |
| Qol Medical, LLC | $30.42 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $15.59 | 2023 | Ibsrela |
| Echosens North America, INC. | $10.15 | 2023 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shirly Ramchandani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.